Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	1,523	1,245	1,128	2,581	1,600	1,832
Market Cap Growth	3.03%	10.35%	-56.28%	61.30%	-12.63%	-36.49%
Enterprise Value	1,219	1,081	1,171	2,565	1,646	1,412
PE Ratio	15.94	23.88	-33.83	45.18	-536.11	2.91
PS Ratio	12.87	9.48	5.75	10.69	9.78	15.23
PB Ratio	1.89	1.78	1.89	3.14	2.26	2.39
P/FCF Ratio	-76.62	-323.11	9.40	36.60	31.08	-57.44
P/OCF Ratio	44.33	25.12	8.19	32.76	29.32	-62.44
EV/Sales Ratio	10.30	8.23	5.97	10.62	10.06	11.74
EV/EBITDA Ratio	7.67	10.81	17.60	19.97	33.79	1.61
EV/EBIT Ratio	9.98	17.26	121.15	35.32	86.04	1.70
EV/FCF Ratio	-58.60	-280.52	9.76	36.36	31.96	-44.28
Debt / Equity Ratio	0.01	0.01	0.15	0.40	0.64	0.85
Debt / EBITDA Ratio	0.04	0.06	1.32	2.53	9.37	0.74
Debt / FCF Ratio	-0.37	-1.60	0.73	4.60	8.86	-20.39
Quick Ratio	19.03	12.11	0.76	10.24	4.68	64.71
Current Ratio	20.71	14.15	2.67	11.15	5.00	66.09
Asset Turnover	0.15	0.17	0.20	0.19	0.13	0.07
Interest Coverage	219.26	95.50	5.37	3.70	0.70	23.29
Return on Equity (ROE)	13.60%	7.80%	-4.40%	7.20%	-0.40%	67.30%
Return on Assets (ROA)	11.90%	6.70%	-3.30%	4.50%	-0.20%	37.20%
Return on Capital (ROIC)	0.07%	1.42%	-1.88%	9.78%	3.22%	44.98%
Earnings Yield	6.33%	4.19%	-2.96%	2.21%	-0.19%	34.36%
FCF Yield	-1.11%	-0.31%	10.64%	2.73%	3.22%	-1.74%
Buyback Yield / Dilution	-0.82%	-5.27%	2.19%	-2.50%	14.84%	17.91%
Total Shareholder Return	-0.82%	-5.27%	2.19%	-2.50%	14.84%	17.91%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).